Ligand Pharmaceuticals Incorporated is a biotechnology business based in the US. Ligand Pharmaceuticals Incorporated shares (LGND) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $102.51 – a decrease of 6.29% over the previous week. Ligand Pharmaceuticals Incorporated employs 68 staff and has a trailing 12-month revenue of around $167.1 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $102.51 |
|---|---|
| 52-week range | $72.61 - $129.90 |
| 50-day moving average | $108.77 |
| 200-day moving average | $109.42 |
| Wall St. target price | $143.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.22 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $105.62 from 2025-05-07
| 1 week (2025-05-01) | -3.23% |
|---|---|
| 1 month (2025-04-10) | 4.27% |
| 3 months (2025-02-10) | -7.45% |
| 6 months (2024-11-08) | -12.89% |
| 1 year (2024-05-10) | 21.01% |
|---|---|
| 2 years (2023-05-08) | 36.37% |
| 3 years (2022-05-06) | 91.35% |
| 5 years (2020-05-08) | 64.31% |
Valuing Ligand Pharmaceuticals Incorporated stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ligand Pharmaceuticals Incorporated's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ligand Pharmaceuticals Incorporated's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.5271. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ligand Pharmaceuticals Incorporated's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Ligand Pharmaceuticals Incorporated's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $58.3 million.
The EBITDA is a measure of a Ligand Pharmaceuticals Incorporated's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $167.1 million |
|---|---|
| Operating margin TTM | 3.94% |
| Gross profit TTM | $134.6 million |
| Return on assets TTM | 1.66% |
| Return on equity TTM | -0.53% |
| Profit margin | -2.41% |
| Book value | $43.47 |
| Market Capitalization | $2.1 billion |
TTM: trailing 12 months
We're not expecting Ligand Pharmaceuticals Incorporated to pay a dividend over the next 12 months.
Ligand Pharmaceuticals Incorporated's shares were split on a 1603:1000 basis on 1 November 2022 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1603 shares. This wouldn't directly have changed the overall worth of your Ligand Pharmaceuticals Incorporated shares – just the quantity. However, indirectly, the new 37.6% lower share price could have impacted the market appetite for Ligand Pharmaceuticals Incorporated shares which in turn could have impacted Ligand Pharmaceuticals Incorporated's share price.
Over the last 12 months, Ligand Pharmaceuticals Incorporated's shares have ranged in value from as little as $72.61 up to $129.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ligand Pharmaceuticals Incorporated's is 0.972. This would suggest that Ligand Pharmaceuticals Incorporated's shares are less volatile than average (for this exchange).
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida. .
We dug through 60 years of Berkshire Hathaway annual shareholder letters to bring you 9 lessons from Warren Buffett: “The Oracle of Omaha.”
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Thinking of switching from Moomoo? Here are 5 apps like Moomoo that offer valuable benefits
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.